
Commercial Pharma Has a Data Debt Problem. Why Minimum Payments Won't Fix It.
Key Takeaways
- Data abundance has outpaced insight reliability, with duplication and inconsistent rules producing competing “truths” that consume time, undermine trust, and impair commercial execution.
- Inefficiency stems less from purchasing data than from weak systems, context-aware processes, and cross-team alignment on definitions, timing, and intended use.
Fragmented data is eroding trust in pharma insights, and AI raises the stakes. A four-step approach can help organizations pay down their “data debt.”
There are parallels between everyday personal debt and pharma's investments in data and analytics. After years of buying data and technology, many pharma organizations have found themselves with "data debt," where the amount of data and technology has piled up but
In the early 2010s, data were sparse. At the time, I was involved in building patient models based on available CMS data, with a few additional points obtained via a survey and a handful of interviews.1 Soon after, data became increasingly available, creating seemingly endless possibilities for insights.
However, it became rapidly apparent that buying more data
Prolific data within organizations also mean that different teams generate different values for the same metric, undermining trust in the outputs. Even when they’re starting from the same source, different rules and timing of insight extraction can result in each group reaching a completely different worldview than the others. This devolves into an exercise of determining whose number is right, forcing reconciliation meetings and an undercurrent of a zero-sum game.
There’s a quantitative cost in the form of meeting time, along with delayed launches and mis-targeted field activity.
What Is Pharma’s Greatest Inefficiency?
There is no doubt that data is a valuable asset. However, data investments need to consider more than the initial purchase and include the systems and processes that make it work.2 Otherwise, data of varying quality (including potential duplication or misalignment) ingested into systems lacking the context in which it is going to be used by different groups results in what I believe is the greatest source of inefficiency in pharma and contributes to the data debt.
Even good data, when it lacks intentional management that considers the data source's and users' context, erodes trust in data, systems, processes, insights, and even colleagues.3
As this debt accumulates, the race to add AI on top of a fragmented data foundation increases the interest rate, amplifying the effects at machine speed and scale, including hallucinations or inaccurate outputs.
As the stakes get higher and internal and external stakeholders expect high-quality, tailored information faster, the debt that organizations have accumulated around data and poor system processes is becoming more obvious.
Just as in everyday life, individuals are starting to ask, “Does it really need to be this way?”
What Are the Steps for Pharma to Get Out of Data Debt?
Similar to paying off debt, making only the minimum payments is going to be the longest, slowest and most expensive path. Devising a plan to make larger payments and get into the black faster requires the following steps:
- Pick a problem. Whether it’s product profitability or field alerts, make it something that will deliver real business value. Understand all perspectives regarding the definition of the problem, what it impacts, and what success would look like after the problem has been solved.
- Design for users. Organizations are collections of humans. If the solution is not helpful to their daily work, they will not use it. Engage them in the design and testing. Gather feedback along the way and incorporate it. One person or team cannot pay this off; it needs to be a collective effort.
- Plan for value. Break down the build into components: data ingestion, data quality, master data management and reporting. In my experience, most specific business problems can be completed in less than six months. Plan for that and inventory the “micro-assets” you build along the way, such as mastered “customer” or “product” domain data and/or data quality rules.
- Use it again. Once you have a repository of micro-assets from your first use case, these can be repurposed for the next business problem. The second should take less than six months, with the third occurring in even less time. The reduction in time to solve isn’t always linear, but it accelerates overall. Along the way, make sure to celebrate wins and build internal momentum around a program that uses technology to solve problems that deliver business value.
This four-step approach enables a program that is meaningful, specific and scalable, allowing an organization to pay down the debt of any data investments, namely those that have lacked proper management and require regular payments.
How to Make Increasingly Larger Payments
A recent pharma client used this process to roll out new reporting across each of its commercial teams. The first use case took about eight weeks because a new data model was needed.
The next rollout took four weeks, and the third required only three weeks from design through build. Team members saw a decrease in reconciliation meetings and a boost in data trust, allowing them to execute against plans with confidence.
If there’s an epilogue, it would be to avoid re-accumulating this debt. Not doing so would be the data equivalent of paying off a credit card and then maxing it out again. As organizations build reusable data assets, they should also strengthen the capabilities needed to manage and maximize their value. Governance guardrails and an intake process for new data sources and tools can prevent the accumulation of new data debt.
There’s rarely a way of quickly paying off a years-long debt. However, being intentional, breaking the process down into pieces and collectively addressing the issue can smooth the path and generate returns faster than many expect.
Clare Gora is partner at Beghou.
References
- CMS Announces Data and Information Initiative. Centers for Medicare & Medicaid Services. June 5, 2012. Accessed November 16, 2026.
https://www.cms.gov/newsroom/fact-sheets/cms-announces-data-and-information-initiative - Labarrère N, Costa L, Lima RM. Data Science Project Barriers: A Systematic Review. Data. 2025;10:132. Accessed November 16, 2026. doi:10.3390/data10080132
- Guillen-Aguinaga M, Aguinaga-Ontoso E, Guillen-Aguinaga L, et al. Data Quality in the Age of AI: A Review of Governance, Ethics, and the FAIR Principles. Data. 2025;10:201. Accessed November 16, 2026. doi:10.3390/data10120201
Related to this article








